Literature DB >> 30240304

Predicting Survival Using Pretreatment CT for Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Comparison of Models Using Radiomics.

Jonghoon Kim1, Seung Joon Choi2, Seung-Hak Lee1, Ho Yun Lee3, Hyunjin Park4,5.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the use of radiomics features as prognostic biomarkers for predicting the survival of patients treated with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: We retrospectively analyzed 88 patients with HCC treated with TACE. High-dimensional quantitative feature analysis was applied to extract 116 radiomics features of pretreatment CT. A radiomics score model was constructed from these features with the use of least absolute shrinkage and selection operator Cox regression. A clinical score model was constructed from clinical variables with the use of multivariate Cox regression. A combined score model was constructed using the radiomics and clinical models. We compared the three models (the radiomics score, clinical score, and combined score models) for predicting overall survival, using Kaplan-Meier analysis and the log-rank test.
RESULTS: The following radiomics features were selected for the radiomics score model: histogram-based features (median, kurtosis, and energy), shape-based features (spherical disproportion and surface-to-volume ratio), gray-level co-occurrence matrix (GLCM)-based features (energy, informational measure of correlation, maximum probability, contrast, and sum average), and intensity size zone matrix-based features (size zone variability). For the clinical score model, the Child-Pugh score, α-fetoprotein level, and HCC size were included. The combined score model included five radiomics features (surface area-to-volume ratio, kurtosis, median, gray-level co-occurrence matrix contrast, and size zone variability) and three clinical factors (Child-Pugh score, α-fetoprotein level, and HCC size). The combined model was a better predictor of survival (hazard ratio, 19.88; p < 0.0001) than the clinical score model or the radiomics score model.
CONCLUSION: A radiomics approach combined with conventional clinical variables could be effective in predicting the survival of patients with HCC treated with TACE.

Entities:  

Keywords:  MDCT; hepatocellular carcinoma; statistical data analysis; survival analysis; therapeutic chemoembolization

Mesh:

Substances:

Year:  2018        PMID: 30240304     DOI: 10.2214/AJR.18.19507

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  31 in total

Review 1.  Radiomics of hepatocellular carcinoma.

Authors:  Sara Lewis; Stefanie Hectors; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2021-01

Review 2.  Radiomics of hepatocellular carcinoma: promising roles in patient selection, prediction, and assessment of treatment response.

Authors:  Amir A Borhani; Roberta Catania; Yuri S Velichko; Stefanie Hectors; Bachir Taouli; Sara Lewis
Journal:  Abdom Radiol (NY)       Date:  2021-04-23

Review 3.  Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma.

Authors:  Emily Harding-Theobald; Jeremy Louissaint; Bharat Maraj; Edward Cuaresma; Whitney Townsend; Mishal Mendiratta-Lala; Amit G Singal; Grace L Su; Anna S Lok; Neehar D Parikh
Journal:  Aliment Pharmacol Ther       Date:  2021-08-12       Impact factor: 9.524

4.  Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm.

Authors:  Huan-Huan Chong; Li Yang; Ruo-Fan Sheng; Yang-Li Yu; Di-Jia Wu; Sheng-Xiang Rao; Chun Yang; Meng-Su Zeng
Journal:  Eur Radiol       Date:  2021-01-14       Impact factor: 5.315

5.  Prediction of Hepatocellular Carcinoma Response to Transcatheter Arterial Chemoembolization: A Real-World Study Based on Non-Contrast Computed Tomography Radiomics and General Image Features.

Authors:  Zheng Guo; Nanying Zhong; Xueming Xu; Yu Zhang; Xiaoning Luo; Huabin Zhu; Xiufang Zhang; Di Wu; Yingwei Qiu; Fuping Tu
Journal:  J Hepatocell Carcinoma       Date:  2021-07-09

6.  Differentiating low and high grade mucoepidermoid carcinoma of the salivary glands using CT radiomics.

Authors:  Michael H Zhang; Adam Hasse; Timothy Carroll; Alexander T Pearson; Nicole A Cipriani; Daniel T Ginat
Journal:  Gland Surg       Date:  2021-05

7.  Peritumoral Dilation Radiomics of Gadoxetate Disodium-Enhanced MRI Excellently Predicts Early Recurrence of Hepatocellular Carcinoma without Macrovascular Invasion After Hepatectomy.

Authors:  Huanhuan Chong; Yuda Gong; Xianpan Pan; Aie Liu; Lei Chen; Chun Yang; Mengsu Zeng
Journal:  J Hepatocell Carcinoma       Date:  2021-06-09

8.  Prognostic Value of Pre-Treatment CT Radiomics and Clinical Factors for the Overall Survival of Advanced (IIIB-IV) Lung Adenocarcinoma Patients.

Authors:  Duo Hong; Lina Zhang; Ke Xu; Xiaoting Wan; Yan Guo
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

9.  Hepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features.

Authors:  Marcello Andrea Tipaldi; Edoardo Ronconi; Elena Lucertini; Miltiadis Krokidis; Marta Zerunian; Tiziano Polidori; Paola Begini; Massimo Marignani; Federica Mazzuca; Damiano Caruso; Michele Rossi; Andrea Laghi
Journal:  Diagnostics (Basel)       Date:  2021-05-26

10.  Radiomic analysis of MRI to Predict Sustained Complete Response after Radiofrequency Ablation in Patients with Hepatocellular Carcinoma - A Pilot Study.

Authors:  Natally Horvat; Jose de Arimateia B Araujo-Filho; Antonildes N Assuncao-Jr; Felipe Augusto de M Machado; John A Sims; Camila Carlos Tavares Rocha; Brunna Clemente Oliveira; Joao Vicente Horvat; Claudia Maccali; Anna Luísa Boschiroli Lamanna Puga; Aline Lopes Chagas; Marcos Roberto Menezes; Giovanni Guido Cerri
Journal:  Clinics (Sao Paulo)       Date:  2021-07-16       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.